Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins

B Schneider1, S Münké1, A Krippner-Heidenreich2, I Grunwald3, WS Wels4, H Wajant5, K Pfizenmaier*1, and J Gerspach1

In an attempt to improve TRAIL’s (tumor necrosis factor-related apoptosis-inducing ligand) tumor selective activity a variant was designed, in which the three TRAIL protomers are expressed as a single polypeptide chain (scTRAIL). By genetic fusion with a single-chain antibody fragment (scFv) recognizing the extracellular domain of ErbB2, we further equipped scTRAIL with tumor-targeting properties. We studied tumor targeting and apoptosis induction of scFv-scTRAIL in comparison with non-targeted scTRAIL. Importantly, the tumor antigen-targeted scTRAIL fusion protein showed higher apoptotic activity in vitro, with a predominant action by TRAIL-R2 signaling. Pharmacokinetic studies revealed increased plasma half-life of the targeted scTRAIL fusion protein compared with scTRAIL. In vivo studies in a mouse tumor model with xenotransplanted Colo205 cells confirmed greater response to the ErbB2-specific scTRAIL fusion protein compared with non-targeted scTRAIL both under local and systemic application regimen. Together, in vitro and in vivo data give proof of concept of higher therapeutic activity of tumor-targeted scFv-scTRAIL molecules. Further, we envisage that through targeting of scTRAIL, potential side effects should be minimized. We propose that scFv-mediated tumor targeting of single-chain TRAIL represents a promising strategy to improve TRAIL’s antitumoral action and to minimize potential unwanted actions on normal tissues.

Cell Death and Disease (2010) 1, e68; doi:10.1038/cddis.2010.45; published online 26 August 2010

Subject Category: Cancer

Although for many malignancies traditional cytotoxic chemotherapy is still the treatment of choice, targeted therapies gain increasing importance because they are expected to exert higher tumor-specific activity and less dose-limiting side effects. The anti-CD20 antibody Rituximab and the Bcr-Abl-selective kinase inhibitor Gleevec, respectively, are two vivid examples for the success of targeted therapy (for review, see Gerber et al.). Targeting the apoptotic machinery of malignant cells has become an attractive concept, beginning with tumor necrosis factor (TNF) and its now established clinical use for locoregional treatment of limb metastases of soft tissue sarcoma and melanoma and followed by the current exploitation of other proapoptotic members of the TNF ligand family – CD95L and TNF-related apoptosis-inducing ligand (TRAIL) – being presently at various stages of preclinical and clinical development (for review, see Call et al. and Gerspach et al.2). TRAIL, similar to TNF a type II transmembrane protein, is expressed on various immune effector cells and appears critically involved in antitumor responses in the body.8 It is probably the best candidate of a death ligand for systemic application because preclinical studies revealed that, in contrast to TNF and CD95 agonists, the application of trimeric, soluble TRAIL is well tolerated. Concomitantly, it demonstrated potent antitumoral activity in tumor models based on tumor cell lines and primary tumor samples.7–10 Although first clinical trials in various advanced cancers are promising, as stable disease has been reported in many cases, TRAIL monotherapy most likely will not result in a sufficient overall therapeutic activity.11 Concurrently, this faces the potential problem that under combined treatment options normal cells might also be sensitized to TRAIL-induced apoptosis (reviewed by Falschelechner et al.12). Furthermore, we have recently shown that TRAIL-R1 is activated by the soluble as well as the membrane-bound form of the ligand, whereas TRAIL-R2 is preferentially activated by membrane TRAIL or oligomerized soluble trimeric TRAIL.13,14 As agonistic TRAIL-R2-specific antibodies likewise display potent antitumor activity (reviewed by Johnstone et al.15), it is conceivable that homotrimeric antibodies could be improved in its activity provided efficient TRAIL-R2 signaling is ensured through genetic modifications or other means. On the other hand, the spontaneous
aggregation of some recombinant TRAIL preparations, resembling secondarily crosslinked TRAIL, has been asso-
ciated with unwanted actions on normal tissues and thus curtail their use as tumor-selective apoptosis inducers (reviewed by Koschny et al.16). Thus, TRAIL variants mimicking the full bioactivity of membrane TRAIL could present powerful cancer therapeutics provided that a tumor-
restricted action can be achieved. A further apparent limitation of the currently clinically investigated recombinant TRAIL reagents is their rather short in vivo half-life. Therefore, an improvement of pharmacokinetic properties might also lead to increased therapeutic action. A potential solution to increase specific activity and bioavailability is the combination of TRAIL function with tumor targeting. Thus, we generated new TRAIL fusion proteins containing an antibody fragment (single-chain Fv fragment (scFv)) for targeting TRAIL to the tumor to enrich the therapeutic at the tumor site and to enhance its specific bioactivity. ErbB2, similar to EGFR/ErbB1, ErbB3 and ErbB4 belonging to the ErB receptor tyrosine kinase family, represents a clinically relevant target antigen. It is highly expressed on a variety of human solid tumors (reviewed by Holbro and Hynes17) and there is already one humanized monoclonal antibody (mAb) directed against the extracellular domain of ErbB2 in clinical use (Trastuzumab) and approved for treatment of breast carcinoma. Several other mAbs are in different stages of clinical evaluation (reviewed by Baselga and Swain18). Although the clinical data provide clear evidence that ErbB2 is a relevant target, they also show that the therapeutic effect of the current antibody reagents is rather limited.19 This justifies the search for additional ErbB2-targeted strategies.

Recently, a single-chain TNF molecule, consisting of three TNF monomers fused by short peptide linkers, was described to exert enhanced stability and antitumoral activity.20 We have designed an analogous single polypeptide chain TRAIL variant (scTRAIL), which was used to construct a scFv–scTRAIL fusion protein for tumor targeting. We have compared the bioactivities of this fusion protein with non-targeted scTRAIL in in vitro and in vivo tumor models. We show here that the tumor antigen-targeted scTRAIL fusion protein showed higher apoptotic activity to scTRAIL in vitro, with a predominant action by TRAIL-R2 signaling on Colo205 colon carcinoma cells. In vivo studies in a mouse xenograft tumor model confirmed significantly higher response to the tumor-targeted ErbB2-specific scTRAIL fusion protein.

Results

Construction and production of TRAIL fusion proteins. To generate a single-chain TRAIL molecule, we followed the design principle described for scTNF20 and covalently fused three TRAIL monomers, each consisting of the extracellular domain of TRAIL (aa 95–281) through two peptide linkers comprising four repeats of the sequence GGGS (Figure 1a). To facilitate purification and analysis an N-terminal FLAG tag was added. Furthermore, by additional N-terminal fusion of a single-chain antibody fragment (scFv) recognizing the FRP5 epitope within the extracellular domain of ErbB2,21 we generated an ErbB2-specific scTRAIL fusion protein (Figure 1a).

Both scTRAIL and scFv–scTRAIL were purified by affinity chromatography on monoclonal M2 anti-FLAG agarose from the supernatant of stably transfected HEK293 cells with yields of about 1 mg protein per liter cell culture supernatant. Immunoblot analysis and SDS-PAGE (Figure 1b) of the purified protein showed single protein bands with a molecular mass of ~70 kDa for scTRAIL and ~100 kDa for scFv–
scTRAIL matching the expected calculated molecular masses of 71 and 98 kDa, respectively. Gel filtration analysis indicated a monomeric organization of both scTRAIL variants, corres-
ponding, with respect to the TRAIL part, to a noncovalently assembled trimer of a conventional recombinant TRAIL molecule (Figure 1c). The molecular masses deduced from SEC were slightly lower compared with that derived from SDS-PAGE (Figure 1b), which did not result from degradation as verified by immunoblot analysis of collected fractions (Figure 1c). In the scTRAIL preparation, the minor fraction eluting in SEC at apparent higher molecular weight, thus potentially comprising aggregated complexes, did not display disproportionately high bioactivity, as revealed from compara-
ison of cytotoxic activity of fraction 2 and 15, taking relative protein amounts into consideration (data not shown).

Target antigen-specific binding of scFv–scTRAIL. To analyze specific binding of scFv–scTRAIL to ErbB2-positive cells, flow cytometry analysis was performed. ErbB2 expres-
sion analysis confirmed a median versus low expression level for Colo205 colon carcinoma and HT1080 fibrosarcoma cells, respectively (Figure 2a), compared with SKBR3 cells that are well-known to highly express the ErbB2 protein (data not shown). Incubation of Colo205 and HT1080 cells with the fusion protein revealed a specific, binding to ErbB2-positive cells (Figure 2a and b) compared with incubation with the non-targeted scTRAIL, which resulted only in a weak fluorescence signal, either by detection with anti-TRAIL (Figure 2a) or with anti-FLAG antibodies (data not shown). As binding of homotrimeric FLAG-tagged TRAIL showed similar weak signals (data not shown), this could reflect a low level of TRAIL receptor (TRAILR) expression on the investigated target cells and/or insufficient sensitivity of FACS analyses. ErbB2-specific binding was confirmed by using TRAILR1- and R2-Fc fusion proteins for detection of scFv–scTRAIL binding to target cells (Figure 2b) and competition with anti-ErbB2 antibodies (FRP5). This led to a near complete inhibition of scFv–scTRAIL binding to the ErbB2-positive cell line (Figure 2b).

Target antigen-restricted induction of cell death by scFv–scTRAIL. To address the bioactivity of scFv–
scTRAIL in vitro, we first analyzed induction of cell death on ErbB2-negative SKW6.4 cells, which are known to be TRAIL-R1 and TRAIL-R2 positive.23,24 (Figure 3a). Although scTRAIL and scFv–scTRAIL did not show cytotoxic activity up to 8 nM, respectively, in the presence of the crosslinking anti-FLAG antibody M2 comparable bioactivities of both fusion proteins were observed (Figure 3a). In contrast, incubation of ErbB2-positive Colo205 and HT1080 cells with scTRAIL or scFv–scTRAIL revealed an approximately three- to fivefold higher bioactivity of the ErbB2-specific scFv–scTRAIL compared with the non-targeted scTRAIL.
Figure 3b: Colo205: EC50scFv–scTRAIL: 30 ± 10 pM, EC50scFv–scTRAIL: 130 ± 70 pM; HT1080: EC50scFv–scTRAIL: 50 ± 5 pM, EC50scFv–scTRAIL: 140 ± 10 pM). Furthermore, bioactivity of the targeted scFv–scTRAIL compared well with that of a commercially available high activity TRAIL, the so-called ‘Killer-TRAIL’, with about twofold higher (Colo205) or at least comparable (HT1080) activity of the scFv–scTRAIL reagent (Figure 3c).

Furthermore, on target-negative SKW6.4 cells, the secondarily crosslinked scTRAIL or scFv–scTRAIL displayed comparable cytotoxic activity to ‘Killer-TRAIL’ (data not shown). From blocking studies using anti-ErbB2 antibodies (FRP5, Figure 3d) or recombinant ErbB2 peptides comprising the epitope of the erbB2-specific scFv21 (Figure 3e), it became evident that the increased bioactivity depended on ErbB2 target binding. Preincubation with FRP5 or ErbB2 peptides before addition of the ErbB2-specific scFv–scTRAIL fusion protein restored cell viability of Colo205 and HT1080 cells to a significant extent (Figure 3d and e). Furthermore, as for both tested cell lines TRAIL-induced cell death is primarily mediated by TRAIL-R2,13,25 the higher bioactivity of the scFv–scTRAIL on ErbB2-positive cells pointed to a membrane TRAIL-mimetic activity upon specific cell surface immobilization of the fusion protein (see below). Furthermore, inhibition of TRAIL bioactivity of the scFv–scTRAIL by the use of a TRAIL-neutralizing antibody led to complete restoration of cell viability of Colo205 and HT1080 cells (Figure 3f). Thus, the ErbB2-specific scFv domain per se did not directly contribute to apoptosis induction.
scFv–scTRAIL molecule signals apoptosis, neutralization experiments with antagonistic, TRAIL-R2-specific monovalent antibody fragments (Fab fragments) were performed. Both ErbB2-positive cell lines showed dominant TRAIL-R2-mediated cell death at low concentrations of scFv–scTRAIL (Figure 4b), demonstrating that cell surface immobilized scFv–scTRAIL exerted membrane TRAIL-like activity, similar to what has been previously described for conventional scFv–TRAIL fusion proteins.13,26,27 The concentration of anti-TRAIL-R2 Fab fragments used in these experiments was sufficient to almost completely block cell death of Jurkat cells induced by secondary crosslinked, homotrimeric FLAG-tagged TRAIL (Figure 4b). In addition, cell surface antigen-bound scFv–scTRAIL also activated the murine TRAILR1, which is, similarly to human TRAIL-R2, not or hardly activated by soluble TRAIL. This was shown by mixed cultures using equal numbers of Colo205 cells and L929 mouse fibroblasts (Figure 4c). The latter do not express human ErbB2 and thus, in contrast to Colo205 cells, are not able to immobilize the scFv–scTRAIL by the ErbB2-targeting domain. Thus, if scFv–scTRAIL is able to induce cell death in L929 cells by mimicking membrane TRAIL after binding to the ErbB2 receptor on Colo205 cells, more than 50% of the cells are expected to die. Indeed, incubation with scFv–scTRAIL induced cell death in about 70% cells of the co-culture, whereas equal molar amounts of scTRAIL induced cell death in only about 30% of the mixed cells (Figure 4c). In mononucleates, the same concentration of scFv–scTRAIL and scTRAIL induced cell death in about 90% of Colo205 cells, respectively, but not in L929 cells, confirming that, in the soluble form, both proteins are non-toxic to the latter (data not shown). Furthermore, due to the lack of human ErbB2, the L929 cells might also be considered as antigen-negative bystander cells, potentially occurring in a tumor tissue. Thus, scFv–scTRAIL bound to antigen is expected to elicit an antitumoral effect also on neighboring antigen-negative cells within the tumor environment.

Figure 2 Target antigen-specific binding of scFv-scTRAIL (a) ErbB2 expression of Colo205 and HT1080 cells: 5 × 10^5 cells were incubated with anti-ErbB2 (gray filled) or isotype control antibody (black lines) followed by FITC-conjugated anti-mouse antibody and fluorescence intensity was measured by FACS analysis. Binding of scFv-scTRAIL to ErbB2-positive Colo205 and HT1080 cells compared with non-targeted scTRAIL: 5 × 10^5 cells were incubated with 50 nM scTRAIL (gray lines) or 50 nM scFv-scTRAIL (gray filled) and, after repeated washes, bound proteins were detected using anti-human TRAIL mAb and FITC-labeled anti-mouse IgG. As control, cells treated with anti-human TRAIL mAb and FITC-labeled anti-mouse IgG were used (black lines). (b) Binding competition of scFv-scTRAIL to ErbB2-positive Colo205 cells by ErbB2-specific antibodies: 5 × 10^5 Colo205 or HT1080 cells were preincubated with FRP5 or mouse IgG1 (10 μg/ml, respectively) before addition of scFv-scTRAIL (50 nM). Detection was carried out by TRAILR-Fc fusion proteins and FITC-labeled anti-human IgG, Fc-specific antibodies. Shown are X-fold increased mean fluorescence intensities (MFI) compared with the control (FITC-labeled anti-human Fc) from three independent experiments (mean ± S.D.). Statistical analysis was carried out with unpaired t-test, two-tailed test, **p = 0.0021, ***p < 0.0001.

TRAIL-R2-mediated apoptosis induction of scFv–scTRAIL. In absence of the ErbB2 antigen, crosslinking of scFv–scTRAIL by its internal FLAG tag with the FLAG-specific mAb M2 was not necessary to induce cell death in SKW (Figure 3a) and in Jurkat cells (Figure 4a). Thus, similar to homotrimeric TRAIL, secondary crosslinking conferred TRAIL-R2-stimulating capacity, confirming the nonaggregated state of the single-chain fusion protein with a TRAIL domain resembling a trimeric soluble TRAIL. The ErbB2-positive Colo205 and HT1080 cells express both, TRAIL-R1 and -R2. To define through which of the two TRAIL death receptors the
clearly discerned. Regimen was 4 daily s.c. injections of 1 nmol of scTRAIL and scFv–scTRAIL, respectively, in an area close to the established tumors. Tumor growth was monitored for 22 days. With this treatment protocol, we observed significant tumor regression in the scFv–scTRAIL-treated group compared not only with the control group (days 1–19; e.g., day 11, \( **P = 0.003 \)) but also with the non-targeted scTRAIL-treated group (days 1–11; e.g., day 11, \(*P = 0.04\), Figure 5b). These data are in accordance with one pilot experiment also showing significantly reduced tumor growth up to 11 days after scFv–scTRAIL treatment started (\( **P < 0.003\), data not shown). These data prompted studies with a systemic treatment protocol to assess the feasibility of such fusion proteins for potential clinical use. Again treatment was initiated when a solid, vascularized tumor had been established. Mice received 8 daily i.v. injections of 1 nmol of the TRAIL fusion proteins or control injections. All treatments were well tolerated by the animals, and we observed no weight loss or other obvious signs of systemic toxicity. Tumor size in control mice increased progressively over the study period (Figure 5c). Similar to the peritumoral treatment, systemic application of the two TRAIL reagents resulted in clear antitumoral activity during treatment. We observed significantly delayed tumor growth on scTRAIL treatment compared with control groups (days 1–19), and an even stronger effect for the tumor-targeted scFv–scTRAIL fusion protein (days 1–19). Remarkably, during scFv–scTRAIL treatment a clear reduction in tumor size was recorded, which resulted in a significantly enhanced antitumoral effect compared with non-targeted scTRAIL (days 1–19). Although tumors of both treatment groups began to re-grow shortly after discontinuation of treatment, these differences remained significant during the complete observation period (e.g., day 19 (Figure 5c)).

**Discussion**

We here show that through genetic engineering and targeting, TRAIL’s antitumoral activity can be improved. TRAIL is considered as a tumor-selective agent, as cells from normal clearly discerned. Regimen was 4 daily s.c. injections of 1 nmol of scTRAIL and scFv–scTRAIL, respectively, in an area close to the established tumors. Tumor growth was monitored for 22 days. With this treatment protocol, we observed significant tumor regression in the scFv–scTRAIL-treated group compared not only with the control group (days 1–19; e.g., day 11, \( **P = 0.003 \)) but also with the non-targeted scTRAIL-treated group (days 1–11; e.g., day 11, \(*P = 0.04\), Figure 5b). These data are in accordance with one pilot experiment also showing significantly reduced tumor growth up to 11 days after scFv–scTRAIL treatment started (\( **P < 0.003\), data not shown). These data prompted studies with a systemic treatment protocol to assess the feasibility of such fusion proteins for potential clinical use. Again treatment was initiated when a solid, vascularized tumor had been established. Mice received 8 daily i.v. injections of 1 nmol of the TRAIL fusion proteins or control injections. All treatments were well tolerated by the animals, and we observed no weight loss or other obvious signs of systemic toxicity. Tumor size in control mice increased progressively over the study period (Figure 5c). Similar to the peritumoral treatment, systemic application of the two TRAIL reagents resulted in clear antitumoral activity during treatment. We observed significantly delayed tumor growth on scTRAIL treatment compared with control groups (days 1–19), and an even stronger effect for the tumor-targeted scFv–scTRAIL fusion protein (days 1–19). Remarkably, during scFv–scTRAIL treatment a clear reduction in tumor size was recorded, which resulted in a significantly enhanced antitumoral effect compared with non-targeted scTRAIL (days 1–19). Although tumors of both treatment groups began to re-grow shortly after discontinuation of treatment, these differences remained significant during the complete observation period (e.g., day 19 (Figure 5c)).

**Figure 3** Target antigen-dependent bioactivity of scFv–scTRAIL. (a) Bioactivity on target antigen-negative cells. 2 × 10⁴ SKW6.4 cells/well were seeded in 96-well plates. The next day, cells were treated with serial dilutions of the fusion proteins in the presence or absence of anti-FLAG M2 antibody (2 μg/ml). (b) Bioactivity of scTRAIL versus scFv–scTRAIL. 5 × 10⁴ Colo205 or 2 × 10⁴ HT1080 cells/well were seeded in 96-well plates. The following day, cells were treated with 2.5 μg/ml cycloheximide and challenged in duplicates with increasing concentrations of scTRAIL and scFv–scTRAIL, respectively. After over night incubation, cell viability was determined by MTT assay or KV staining. Results from three to five independent experiments are shown (mean ± S.D.). (c) Bioactivity of scFv–scTRAIL compared to ‘KillerTRAIL’. Same assay as in b but incubation with serial dilutions of scFv–scTRAIL or ‘KillerTRAIL’. (d, e) Target antigen-dependent apoptosis induction of scFv–scTRAIL. Same assay as in b with scFv–scTRAIL titrated in the presence or absence of anti-ErbB2 (FRP5, 5 μg/ml) (d) or with scFv–scTRAIL (0.05 nM) in the presence or absence of recombinant ErbB2 (10 μg/ml) (e). (f) Contribution of the scFv domain in the scFv–scTRAIL to apoptosis induction. Same assay as in b with scFv–scTRAIL titrated in the presence or absence of neutralizing anti-TRAIL antibodies (2E5, 1 μg/ml). (a, c–f) Results from three independent experiments are shown (mean ± S.D.). (b, d) Statistical analysis was carried out with unpaired t-test. **0.0026 < \( P \) < 0.0008, ***\( P < 0.0001\).
tissue appear largely resistant toward apoptosis induction by trimeric TRAIL derivatives, and clinical studies so far revealed that homotrimeric TRAIL is well tolerated. However, in contrast to many investigated tumor cell lines, diverse primary cancer cells are inherently resistant to TRAIL-mediated apoptosis (reviewed by Newsom-Davis et al.). Moreover, it has been demonstrated that TRAIL may under certain conditions even promote survival, proliferation, migration and invasion in TRAIL-resistant tumor cells. Thus, combination therapy with other drugs will be required, for example, for sensitization of apoptotic pathways or suppression of potentially protumoral TRAIL effects, to achieve major and lasting tumor remissions. In this context, recent data appear of relevance showing that the resistance of nontransformed cells toward the apoptotic action of TRAIL may vanish, at least in some tissues such as the liver, when these are subjected to various stress conditions, such as infection and chemotherapeutics. Recently, it has also been shown that TRAIL-R2-mediated apoptosis might substantially contribute to chronic cholestatic disease. Accordingly, an improvement of the tumor-selective action of TRAIL appears mandatory. Along this line, we and others have already shown earlier that tumor-targeting approaches through the generation of TNF ligand fusion proteins, which aim to restrict TNF ligand's full cytotoxic activity to the cancerous tissue are very promising approaches to improve therapeutic efficacy of TRAIL and other members of the TNF ligand family. Conventional fusion proteins of TRAIL and antibody-derived scFv fragments reveal homotrimeric proteins with a molecular mass of ~150 kDa. This nearly corresponds in size to complete antibodies that are reported to penetrate tumor tissues slowly and nonuniformly.

Figure 4  TRAIL-R2-mediated apoptosis induction of scFv–scTRAIL. (a) $1 \times 10^5$ Jurkat cells/well were seeded in 96-well plates. The following day, cells were challenged with the indicated concentration of scFv–scTRAIL in the absence (open symbols) or presence (filled symbols) of 1 μg/ml of the crosslinking anti-FLAG mAb M2. After additional 16 h, cell viability was determined by MTT assay. (b) Cells ($5 \times 10^5$ Colo205, $2 \times 10^5$ HT1080, $1 \times 10^5$ Jurkat cells/well) were seeded in 96-well plates. The next day, cells were treated with 2.5 μg/ml cycloheximide (HT1080, Colo205) and challenged with scFv–scTRAIL (1.35 nM) (HT1080, Colo205) or 2 nM TRAIL + 1 μg/ml anti-FLAG mAb M2 (Jurkat) in the presence or absence of TRAIL-R2 Fab (50 μg/ml). After additional 16 h, cell viability was determined by MTT assay or KV staining. (c) $1 \times 10^5$ Colo205 and $1 \times 10^5$ L929 cells/well were seeded and co-cultured in 96-well plates. The next day, cells were treated with 2.5 μg/ml cycloheximide and challenged with 1 nM scTRAIL or scFv–scTRAIL. After additional 16 h, cell viability was determined by MTT assay. (a–c) Results from three independent experiments are shown (mean ± S.D.).
Furthermore, antibody fragments may have an intrinsic tendency to aggregate, thereby potentially leading to higher order complexes, which in turn not only results in a further increase in size but may also cause target-independent TRAIL-R2 activity, too. To circumvent or at least minimize these potential problems, we have developed a new format of a TRAIL fusion protein based on scTRAIL, a single polypeptide chain composed of three TRAIL monomers. Gel filtration and western blot analysis revealed that the ErbB2-specific scFv–scTRAIL fusion protein could be expressed in the expected monomeric state corresponding formally to a trimeric TRAIL variant. This is of great importance, as it became evident that the formation of high order complexes and aggregates of recombinant forms of TRAIL (e.g., His-TRAIL, crosslinked FLAG–TRAIL) increases the toxicity of the ligand to normal cells (reviewed by Koschny et al.16).

As expected, the ErbB2-specific scFv–scTRAIL specifically bound to ErbB2-positive cells. This could be confirmed by the use of TRAILR-Fc fusion proteins to detect the ErbB2 bound scFv–scTRAIL and by blocking of fusion protein binding with the ErbB2-specific antibody FRP5, thereby indicating predominant binding of the fusion protein by the antibody.
Furthermore, we can exclude an effect of the ErbB2-specific antibody fragment scFvFRP5 on tumor growth, as addition of TRAIL-neutralizing antibodies completely restored cell viability on incubation with scFv–scTRAIL.

This is in accordance with previous reports showing that the mAb FRP5 did not affect tumor growth in vivo, despite even partial agonistic activity in vitro, evident from an increase in ErbB2 phosphotyrosine level and accelerated receptor turnover by antibody-mediated receptor crosslinking. In contrast, a monovalent scFvFRP5–ETA fusion protein did not induce ErbB2-tyrosine phosphorylation, indicating that the activity of a monovalent scFv fusion protein might be limited by the intrinsic turnover rate of its target receptor. We have own preliminary data confirming an increase in ErbB2-phosphorylation on treatment of Colo205 cells with a conventional, homotrimeric scFv-FRP5–TRAIL fusion protein, whereas treatment with the monovalent scFv–scTRAIL had no receptor-activating effect (data not shown). Accordingly, the single-chain design concept might be of advantage compared with a conventional fusion protein if target-antigen multimerization has to be avoided. Moreover, Stagg et al. could show that combination of ErbB2 blockade and TRAIL-R2 activation can elicit potent synergistic antitumor activity. Thus, modifying the targeting module using an ErbB2-specific scFv antibody fragment also capable of inhibiting ErbB2 signaling might result in further increased ErbB2-specific antitumor activity of an scFv–TRAIL fusion protein. The here described antitumoral activity of the scFv–scTRAIL fusion protein, which resulted in clear reduction in tumor size under treatment, appears superior to that of published preclinical data with homotrimERIC TRAIL, regarding both the applied dose and the treatment periods. However, detailed side-by-side comparison of different TRAIL reagents are required to confirm this observation.

In conclusion, our data provide evidence that bioactive single-chain TRAIL fusion proteins can be generated. Furthermore, fusion to a target-specific scFv antibody results in target-dependent increase in TRAIL-mediated cytotoxicity in vitro, likely due to efficient TRAIL-R2 activation, and improves antitumoral activity in vivo. Accordingly, this design concept represents a promising strategy to enhance TRAIL’s antitumoral action and to minimize potential unwanted off-target actions on normal tissues.

Materials and Methods

Plasmids and cell lines. The pIRESpuro–scTRAIL expression construct for human scTRAIL (aa 95–281) was generated by insertion of linker sequences, encoding four repetitions of the GGSS motif, between the three TRAIL modules as described previously for the construction of scTNF.

The single-chain antigen binding protein scFvFRP5 for the ErbB2-specific pIRESpuro–scFv–scTRAIL expression construct was described previously. The single-chain antibody protein scFvFRP5 for the ErbB2-specific pIRESpuro–scFv–scTRAIL expression construct was described previously. The single-chain antibody protein scFvFRP5 for the ErbB2-specific pIRESpuro–scFv–scTRAIL expression construct was described previously. The single-chain antibody protein scFvFRP5 for the ErbB2-specific pIRESpuro–scFv–scTRAIL expression construct was described previously. The single-chain antibody protein scFvFRP5 for the ErbB2-specific pIRESpuro–scFv–scTRAIL expression construct was described previously. The single-chain antibody protein scFvFRP5 for the ErbB2-specific pIRESpuro–scFv–scTRAIL expression construct was described previously. The single-chain antibody protein scFvFRP5 for the ErbB2-specific pIRESpuro–scFv–scTRAIL expression construct was described previously. The single-chain antibody protein scFvFRP5 for the ErbB2-specific pIRESpuro–scFv–scTRAIL expression construct was described previously. The single-chain antibody protein scFvFRP5 for the ErbB2-specific pIRESpuro–scFv–scTRAIL expression construct was described previously.

Production and purification of recombinant proteins. The TRAIL fusion proteins were produced in HEK293 cells after stable transfection of the corresponding expression plasmids using Lipofectamine 2000 (Invitrogen) and selection of stable clones by limiting dilution. For protein production, stable clones were expanded and grown in RPMI 1640, 5% FCS, to 90% confluency and
subsequently cultured in serum-free OptiMEM (Invitrogen) supplemented with 50 μM ZnCl₂, replacing media two times every 3 days. Supematants were pooled and recombinant proteins were purified by affinity chromatography using anti-FLAG mAb M2 agarose (Sigma-Aldrich, Steinheim, Germany). The bound proteins were eluted with 100 μg/ml FLAG peptide (Sigma-Aldrich) and dialyzed against PBS. After concentrating purified proteins by dialysis on PEG35000, they were analyzed and quantified by SDS-PAGE, silver gel (Sigma-Aldrich) and gel filtration and stored at 4°C.

**Gel filtration.** Protein samples were applied to a BioSuite250 HR SEC (300 × 7.8 cm) (Waters, Milpore Corp., Milford, MA, USA) equilibrated in PBS and eluted at a flow rate of 0.5 ml/min.

**Flow cytometry.** Cells (5 × 10⁴) were incubated for 2 h at 4°C with the indicated concentrations of the TRAIL fusion proteins. After washing the cells three times with PBS, 2% FCS, 0.02% sodium azide, bound fusion proteins were detected by anti-human TRAIL mAb (MAB8687) (1 μg/ml, R&D Systems, Wiesbaden, Germany) and fluorescein isothiocyanate-labeled rabbit anti-mouse IgG Ab (1 μg/ml, Sigma-Aldrich). ErbB2 expression was detected by anti-c-neu (AB-5) (1 μg/ml, Merck KGaA, Darmstadt, Germany) and fluorescein isothiocyanate-labeled rabbit anti-mouse IgG Ab (1 μg/ml, Sigma-Aldrich). Alternatively, cell-bound scFv–scTRAIL was detected by TRAILR-Fc fusion proteins (5 μg/ml TRAILR1-Fc and 3 μg/ml TRAILR2-Fc) and fluorescein isothiocyanate-labeled anti-human IgG, Fc-specific antibodies (Sigma-Aldrich). For competition studies, FRPS hybridoma supernatant or mouse IgG1 (Sigma-Aldrich) was added 30 min before addition of the scFv–scTRAIL.

**Cell death assays.** HT1080 cells (2 × 10⁵/well), Colo205 cells (5 × 10⁵/well), SKW6.4 cells (2 × 10⁵/well) or Jurkat cells (1 × 10⁵/well) were cultured in 100 μl culture medium in 96-well plates. The next day, cells were treated in duplicates or triplicates with the indicated concentrations of the TRAIL fusion proteins or ‘Killer-TRAIL’ (Axxora Deutschland GmbH, Lörach, Germany). After over night incubation, cell viability was determined either by crystal violet staining (HT1080) or the MTT test (Jurkat, Colo205, SKW6.4), except that for MTT staining a lysis buffer consisting of 15% SDS in DMF/dH₂O (1:1); pH4.5 (with 80% acetic acid) was used. To show target antigen- and TRAIL-R2-dependent induction of cell death, cells were preincubated for 30 min with FRPS hybridoma supernatant (~10 μg/ml) or a competing ErbB2 peptide (10 μg/ml) encompassing the FRPS-binding epitope or a neutralizing TRAIL-R2-specific Fab preparation (50 μg/ml), respectively. For inhibition of TRAIL bioactivity, anti-TRAIL antibody 2E5 (1 μg/ml, Axxora Deutschland GmbH) was used. For co-culture assays, 1 × 10⁴ Colo205 and 1 × 10⁵ L929 cells/well were seeded in 96-well plates. The next day, cells were challenged in duplicates with scFv and scFv–scTRAIL, respectively. After additional 16 h, cell viability was determined using the MTT test method. Cell death assays with HT1080 and Colo205 cells were performed in the presence of 2.5 μg/ml cycloheximide (Sigma-Aldrich) to sensitize cells for the induction of cell death.

**Pharmacokinetics.** Animal care and all experiments performed were in accordance with federal guidelines and have been approved by the University and State authorities. Baldic mice (female, 7 weeks, weight between 18 and 20 g, 3 mice/group) received an i.v. injection of 400 pmol of the recombinant proteins in a total volume of 100 μl. In time intervals of 2, 6, 20, 60, 120, 240, 360 min and 24 h, blood samples (~100 μl) were taken from the tail and incubated on ice. Clotted blood was centrifuged at 10 000 × g for 10 min, 4°C, and serum samples were stored at −80°C. Serum concentrations of recombinant proteins were finally determined by ELISA (BD Biosciences, Heidelberg, Germany). For calculation, relative values of serum concentrations were analyzed with the first value (2 min) being set to 100%.

**Acknowledgements.** We gratefully acknowledge technical support in the initial expression of scTRAIL by Sylvia Willy. Our work is supported by grants from Deutsche Krebshilfe, Grant no. 107551 and 108268 to HW and KP, from BMBF (Biochance plus, FKZ 0315164) to KP and by a career fellowship award by the Peter and Traudl Engelhorn Foundation to JG.

1. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008; 77: 311–319.
2. Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immunol 2006; 8: 6.
3. Cell JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 2008; 9: 1002–1011.
4. Gerspach J, Wajant H, Pfenninger M. Death ligands designed to kill development and application of targeted cancer therapeutics based on pro-apoptotic TNF family ligands. Results Probl Cell Differ 2009; 49: 241–273.
5. Newsom-Davis T, Prieke S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis 2009; 14: 607–623.
6. Wajant H. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Rev 2006; 130: 141–165.
7. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Mansters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–182.
8. Walczak H, Miller RE, Anai K, Gliniak B, Griffith TS, Kubin M et al. Tumoridal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.
9. Naka T, Sugamura K, Hylande BL, Widmer MB, Rustum YM, Rassay EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand and in combination with chemotherapeutic agents on patients’ colon tumors grown in SCID mice. Cancer Res 2002; 62: 5800–5806.
10. Hylande BL, Plotnik R, Penettrand RB, Gibbs JJF, Oktay D, Cheng J et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005; 3: 22.
11. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008; 118: 1979–1990.
12. Falschlehner C, Ganten TM, Koschny R, Schaefer U, Walczak H. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 2009; 647: 195–206.
13. Wajant H, Moosmayer D, Wiest T, Bartke T, Gerlach E, Schonherr U et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface apoptosis signaling. J Biol Chem 2005; 280: 22055–22063.
14. Wajant H, Ciechanover A. TRAIL and DR5: what a duet in cancer therapy. Nat Rev Cancer 2004; 4: 195–217.
15. Baserga J, Swan SM. Novel anticancer targets: reviving ERBB2 and discovering ERBB3. Apoptosis 2009; 14: 463–475.
16. Hynes NE. EGF receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2009; 49: 141–163.
Tumor-targeted single-chain TRAIL for cancer therapy
B Schneider et al

22. Hynes NE, Gerber HA, Saurer S, Groner B. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem 1989; 39: 167–173.

23. Luciano F, Ricci JE, Herrant M, Bertolotto C, Mari B, Cousin JL et al. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) fusion protein with specificity for human CD95. Int J Cancer 2004; 109: 281–290.

24. Muhlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G et al. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in tumor necrosis factor-related apoptosis-inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64: 2580–2589.

25. Ling J, Herbst RS, Mendelson DS, Eckhardt SG, O'Dwyer P, Ebbinghaus S et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003; 22: 3842–3852.

26. Volkman X, Fischer U, Bahr MJ, Ott M, Lehner F, MacFarlane M et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007; 46: 1498–1508.

27. Babu CK, Suvarnamrin K, Bren GD, Badley AD, Rizza SA. HIV induces TRAIL sensitivity in hepatocytes. PLoS One 2009; 4: e6823.

28. Mundt B, Winh T, Zender L, Wallethne M. Tumor necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005; 54: 1590–1596.

29. Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, Okamura K et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci USA 2008; 105: 10895–10899.

30. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126–1136.

31. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebaid W et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 2007; 14: 2021–2029.

32. Assouh-Luty C, Gerspach J, Siegmund D, Muller N, Huard B, Tieg G et al. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med 2008; 84: 785–797.

33. Koleski JS. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420–430.

34. Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandon E. Tissue distribution, stability, and pharmacokinetics of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 2004; 32: 1233–1238.

35. Hanwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993; 68: 1140–1145.

36. Wels W, Moritz D, Schmidt M, Jeschke M, Hynes NE, Groner B. Biotechnological and gene therapeutic strategies in cancer treatment. Gene 1995; 159: 73–80.

37. Shah J, Sharkey J, Pommey S, Young R, Takeda K, Yagita H et al. Antibodies targeted to TRAIL-receptor 2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc Natl Acad Sci USA 2008; 105: 16254–16259.

38. Wuest T, Gerfach E, Banerjee D, Gerspach J, Moosmayer D, Pfizenmaier K. TNF-Selectrokine: a novel produg generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene 2002; 21: 4257–4265.

39. Hanwerth IM, Wels W, Marte BM, Hynes NE. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 1992; 267: 19871–19876.

40. Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987; 138: 963–974.